MEIP - Dosing underway for Kyowa Kirin/MEI Pharma's zandelisib mid-stage study in blood cancer

Kyowa Kirin (KYKOF) and MEI Pharma (MEIP) have dosed the first patient in Phase 2 study of zandelisib (ME-401) for the treatment of indolent B-cell non-Hodgkin's lymphoma (iNHL) without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström's macroglobulinemia in Japan.The study is conducted by Kyowa Kirin to evaluate zandelisib as monotherapy for treatment relapsed or refractory iNHL with at least two prior systemic therapies.In April, MEI and Kyowa Kirin announced license, development, and commercialization agreement to further develop and commercialize zandelisib.ME-401 inhibits phosphatidylinositol 3-kinase delta (PI3K?) that plays a key role in the activation, proliferation and survival of B cells.

For further details see:

Dosing underway for Kyowa Kirin/MEI Pharma's zandelisib mid-stage study in blood cancer